Fiocruz to produce first oral antiviral against covid in Brazil

The drug reduces up to 89% of covid-19 mortality, according to US pharmaceutical company MSD. The Oswaldo Cruz Foundation (Fiocruz) will be responsible for providing the drug to the Brazilian Unified Health System (SUS).

RIO DE JANEIRO, BRAZIL - On May 5, Farmanguinhos/Fiocruz (Pharmaceutical Technology Institute of the Oswaldo Cruz Foundation) announced a technological cooperation agreement with the US pharmaceutical company MSD (Merck Sharp & Dohme) to produce molnupiravir in Brazil, the first oral antiviral drug to treat Subscribe to our Premium Membership Plan. Already Subscribed?